Southern Health and Social Care Trust

TOGETHER, IMPROVING CARE, TRANSFORMING LIVES

Information Governance Team

FOI 3626

12th March 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of October 2025 to the end of December 2025, or the latest three-month period for which data is available. Please include data for all hospitals within Southern Health & Social Care Trust

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Response:

Name of medicine		Number patients treated
1.1 Abemaciclib (Verzenios)		27
1.2 Alpelisib (Piqray)		0
1.3 Elacestrant (Orserdu)		<5
1.4 Fulvestrant (fulvestrant or Faslodex)		Not dispensed at patient level by pharmacy and administered through RISOH
1.5 Inavolisib (Inaqovi)		0
1.6 Palbociclib (Ibrance)		24
1.7 Ribociclib (Kisqali)		14
1.8 Capivasertib (Truqap)		<5
1.9 Talazoparib (Talzenna)		0
1.10 Olaparib (Lynparza)		<5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all

information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q2. How many patients received the following medicines for <u>early breast cancer</u> in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy		Number patients treated
2.1 Abemaciclib (Verzenios)		
2.2 Ribociclib (Kisqali)		
2.3 Olaparib (Lynparza)		

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q3. How many patients received the following medicines with <u>curative</u> treatment intent in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy		Number patients treated
3.1 Abemaciclib (Verzenios)		
3.2 Ribociclib (Kisqali)		

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Name of combination or monotherapy		Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)		
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)		
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)		

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of October 2025 and the end of December 2025?

Type of breast cancer		Number patients treated
5.1 Olaparib - All types of breast cancer		
5.2 Olaparib - Locally advanced or metastatic breast cancer		
5.3 Talazoparib – All types of breast cancer		

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q6. How many patients were treated in total with the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Response:

Name of medicine		Number patients treated
6.1 Pertuzumab (Perjeta)		0
6.2 Pertuzumab with Trastuzumab (Phesgo)		36
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)		23
6.4 Trastuzumab Deruxtecan (EnHertu)		7
6.5 Trastuzumab Emtansine (Kadcyla)		7
6.6 Tucatinib (Tukysa)		0
6.7 Neratinib (Nerlynx)		

Q7. How many patients were treated with the following products for a diagnosis of <u>Breast Cancer</u> *(ICD-10 codes = C50*, D509)* in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine		Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)		
7.2 Trastuzumab Deruxtecan (EnHertu)		

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Products		Number patients treated
8.1 Pertuzumab (Perjeta)		
8.2 Pertuzumab with Trastuzumab (Phesgo)		
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)		
8.4 Trastuzumab Emtansine (Kadcyla)		

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if

information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Products		Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)				
9.2 Pertuzumab with Trastuzumab (Phesgo)				
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)				
9.4 Trastuzumab Emtansine (Kadcyla)				

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Treatment intent		Number patients treated
10.1 HER2+ve Breast Cancer		
10.2 HER2-low Breast Cancer		

Response:
This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for

the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Email: foi.team@southerntrust.hsci.net